Affomix

In a recent interview with ProteoMonitor, Swiss Federal Institute of Technology Zurich researcher Ruedi Aebersold observed that to a significant extent, proteomics has been constrained by a lack of good affinity reagents (

Anticipating that NGS will become a key clinical tool in coming years, several proteomics firms and researchers are investigating it as a platform for protein biomarker detection assays that use nucleotides as capture agents, hoping to take advantage of the technology's precision and multiplexing ability.

Funding Update

Premium

New NIH Grants for Sequencing-Related Technology and Methods, January-June 2010

Movers & Shakers

Premium

John Boyce, James Slattery, Sam Raees

Paired Ends

Premium

David Weitz, John Boyce

The company will be using its automated, high-throughput monoclonal antibody selection technology to produce several antibodies for each protein target chosen by PGx Centre researchers, enabling them to undertake quantitative, multiplexed profiling of the putative biomarkers.

Affomix and the PGx Centre will develop reagents for the quantitative multiplex profiling of candidate biomarkers that may allow clinicians to predict and evaluate how patients respond to novel anti-atherosclerotic agents.

Affomix will supply City of Hope with monoclonal antibodies that will be used to create proteomic profiles that are characteristic of a number of cancers such as renal and prostate cancers.

City of Hope will then use Affomix's recombinant antibodies to generate proteomic profiles characteristic of a number of cancers, such as renal and prostate.

Affomix will use its Y2HExpress technology to select antibodies for Kalgene with potential diagnostic and therapeutic use in breast cancer.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.